Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Navigo Proteins GmbH has 6 pending office actions in Biotechnology & Pharmaceuticals. The docket spans 6 examiners and 5 art units, creating a broad set of examination relationships with some shared art-unit coverage. This distribution suggests that prosecution management should combine centralized tracking with matter-specific substantive review.
HA, JULIE is the busiest examiner, with 1 pending matter. No examiner accounts for more than 1 reported action, so there is no concentrated examiner relationship to drive portfolio strategy. Counsel should instead look for recurring issues across the biotechnology matters and distinguish them from objections tied to particular art-unit practices.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (50%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HA, JULIE | 1 | 75.7% | +44.1% |
| OGUNTADE, ELIZABETH BISOLA | 1 | 50.0% | +100.0% |
| EIX, EMILY FAY | 1 | 45.7% | +76.0% |
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
| DAHLE, CHUN WU | 1 | 50.2% | +51.1% |
| SALVOZA, M FRANCO G | 1 | 68.2% | +30.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016436 | SERUM STABLE BINDING PROTEINS FOR HUMAN HER2 FOR THERANOSTIC APPLICATIONS | DAHLE, CHUN WU | 16d |
| 18036813 | BINDING PROTEINS FOR COMPLEMENT FACTOR H (CFH) | EIX, EMILY FAY | 61d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18036142 | NEW TYPE II COLLAGEN BINDING PROTEINS | PUTTLITZ, KARL J | 85d overdue |
| 18016436 | SERUM STABLE BINDING PROTEINS FOR HUMAN HER2 FOR THERANOSTIC APPLICATIONS | DAHLE, CHUN WU | 16d |
| 18036813 | BINDING PROTEINS FOR COMPLEMENT FACTOR H (CFH) | EIX, EMILY FAY | 61d |
| 18629324 | SPECIFIC BACULOVIRUS MAJOR ENVELOPE GLYCOPROTEIN GP64 BINDING PROTEINS | HA, JULIE | — |
| 18575743 | Affinity ligands for the purification and detection of ubiquitin muteins | OGUNTADE, ELIZABETH BISOLA | — |
| 18012284 | BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) | SALVOZA, M FRANCO G | — |
| Art Unit | Apps |
|---|---|
| 1677 | 1 |
| 1653 | 1 |
| 1646 | 1 |
| 1641 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18629324 | SPECIFIC BACULOVIRUS MAJOR ENVELOPE GLYCOPROTEIN GP64 BINDING PROTEINS | HA, JULIE | — | §112 | Non-Final OA | — | Pending | Apr 08, 2024 |
| 18575743 | Affinity ligands for the purification and detection of ubiquitin muteins | OGUNTADE, ELIZABETH BISOLA | 1677 | §112 | Non-Final OA | — | Pending | Dec 29, 2023 |
| 18036813 | BINDING PROTEINS FOR COMPLEMENT FACTOR H (CFH) | EIX, EMILY FAY | 1653 | §102§103§112Other | Final Rejection | 61d | Pending | May 12, 2023 |
| 18036142 | NEW TYPE II COLLAGEN BINDING PROTEINS | PUTTLITZ, KARL J | 1646 | §112DP | Final Rejection | 85d overdue | Pending | May 09, 2023 |
| 18016436 | SERUM STABLE BINDING PROTEINS FOR HUMAN HER2 FOR THERANOSTIC APPLICATIONS | DAHLE, CHUN WU | 1641 | §102§112 | Final Rejection | 16d | Pending | Jan 16, 2023 |
| 18012284 | BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) | SALVOZA, M FRANCO G | 1672 | §112 | Non-Final OA | — | Pending | Dec 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNavigo Proteins GmbH has 6 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Julie Ha has the most, with 1 of Navigo Proteins GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
